GEO-MVA-MUC1 / GeoVax - LARVOL DELTA

GeoVax Announces Multiple Patent Issuances and Allowances (GlobeNewswire) - "GeoVax Labs, Inc...announced multiple actions by global patent offices strengthening the Company’s intellectual property assets...The Japanese Patent Office issued a Decision of Grant notifying GeoVax of the allowance of the Company’s Patent Application No. 2022-153352....The allowed claims are directed to recombinant MVA viral vectors comprising specific MUC-1 nucleic sequences used in GeoVax’s MUC-1 tumor-associated antigen immunotherapy program. Pharmaceutical compositions for inducing immune responses, preventing or reducing neoplasm growth, or treating cancer are also covered by the granted claims."

Patent • Oncology • Solid Tumor